Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2008-09-02
2008-09-02
Balasubram, Venkataraman (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C544S184000
Reexamination Certificate
active
10970420
ABSTRACT:
Compounds having the formula (I),and pharmaceutically acceptable salts, prodrugs, and solvates thereof, are useful as kinase inhibitors, wherein R, R1, R2, R5, R6a, R6b, J, K, X and Z are as described in the specification.
REFERENCES:
patent: 4200750 (1980-04-01), Warner, Jr. et al.
patent: 5658903 (1997-08-01), Adams et al.
patent: 5932576 (1999-08-01), Anantanarayan et al.
patent: 5945418 (1999-08-01), Bemis et al.
patent: 5977103 (1999-11-01), Adams et al.
patent: 6087496 (2000-07-01), Anantanarayan et al.
patent: 6130235 (2000-10-01), Mavunkel et al.
patent: 6147080 (2000-11-01), Bemis et al.
patent: 6251914 (2001-06-01), Adams et al.
patent: 6277989 (2001-08-01), Chakravarty et al.
patent: 6492383 (2002-12-01), Munchhof et al.
patent: 6670357 (2003-12-01), Leftheris et al.
patent: 2003/0224184 (2003-12-01), Hermes et al.
patent: 2004/0023992 (2004-02-01), Das et al.
patent: 2004/0082582 (2004-04-01), Dyckman et al.
patent: 0 447 891 (1994-04-01), None
patent: 2 662 163 (1991-11-01), None
patent: WO 95/19774 (1995-07-01), None
patent: WO 96/40142 (1996-12-01), None
patent: WO 97/13771 (1997-04-01), None
patent: WO 99/24440 (1999-05-01), None
patent: WO 00/12074 (2000-03-01), None
patent: WO 00/12497 (2000-03-01), None
patent: WO 00/56738 (2000-09-01), None
patent: WO 01/14378 (2001-03-01), None
patent: WO 01/27089 (2001-04-01), None
patent: WO 01/34605 (2001-05-01), None
patent: WO 02/40486 (2002-05-01), None
Wolft Manfred E. “Burger's Medicinal Chemistry, 5ed, Part 1”, John Wiley & Sons, 1995, pp. 975-977.
Banker, G.S. et al, “Modern Pharmaceutices, 3ed.”, Marcel Dekker, New York. 1996, pp. 451 and 596.
West, Anthony R., Solid State Chemistry and its Applications, Wiley, New York, 1988, pp. 358 & 365.
Vippagunta et al., Advanced Drug Delivery Reviews 48: 3-26, 2001.
Graninger et al. Curr. Opin. Rheumatol. 13(3): 209-213, 2001.
Nagarkatti et al. J. Mol. Cell Cardiol. 30(8): 1651-1664, 1998.
Brunet et al., Esaays Biochem. 32 : 1-16, 1997.
Herlaar et al. Mol. Med. Today 5(10) 439-447,1999.
Anderson, W.K. et al., “Design, Synthesis, Antineoplastic Activity, and Chemical Properties of Bis(carbamate) Derivatives of 4,5-Bis(hydroxymethyl)imidazole”, J. Med. Chem., vol. 32, No. 1, pp. 119-127 (1989).
Bayón, J.C. et al., “Dinuclear Rhodium and Iridium Complexes of Dicarboxyimidazolates; Crystal Structure of [NBu4][(cod)Rh(dcbi)Rh(cod)]•2PriOH”, J. Chem. Soc. Dalton Trans., pp. 3003-3007 (1987).
Brown, D.J. et al., “Isomerisations Akin to the Dimroth Rearrangement. Part II. The Equilibria of 4-Mercapto-1,2,3,5,7-penta-azaindenes with 4-Amino-1-thia-2,3,5,7-tetra-azaindenes”, J. Chem. Soc. (C), pp. 1856-1860 (1967).
Bundgaard, H., Chapter 5: “Design and Application of Prodrugs”, A Textbook of Drug Design and Development, Harwood Academic Publishers, publ., Krogsgaard-Larsen, P. et al., eds., pp. 113-191 (1991).
Bundgaard, H., ed., Design of Prodrugs, Elsevier Science Publishers B.V., publ. (1985) (table of contents).
Bundgaard, H., “Means to Enhance Penetration: Prodrugs as a means to improve the delivery of peptide drugs”, Advanced Drug Delivery Reviews, vol. 8, pp. 1-38 (1992).
Butters, M., “Large Scale Synthesis of 4-Ethylpyrimidine”, J. Heterocyclic Chem., vol. 29, pp. 1369-1370 (1992).
Cohnen, E. et al., “A Simple Synthesis of Pyrroles”, Synthesis, pp. 566-568 (1987).
Henry, J.R. et al., “p38 mitogen-activated protein kinase as a target for drug discovery”, Drugs of the Future, vol. 24, No. 12, pp. 1345-1354 (1999).
Moreland, L.W. et al., “Etanercept Therapy in Rheumatoid Arthritis: A Randomized, Controlled Trial”, Ann. Intern. Med., vol. 130, No. 6, pp. 478-486 (1999).
Raingeaud, J. et al., “MKK3- and MKK6-Regulated Gene Expression Is Mediated by the p38 Mitogen-Activated Protein Kinase Signal Transduction Pathway”, Molecular and Celluar Biology, vol. 16, No. 3, pp. 1247-1255 (1996).
Rankin, E.C.C. et al., “The Therapeutic Effects of an Engineered Human Anti-Tumour Necrosis Factor Alpha Antibody (CDP571) in Rheumatoid Arthritis”, British Journal of Rheumatology, vol. 34, No. 4, pp. 334-342 (1995).
Salituro, F.G. et al., “Inhibitors of p38 MAP Kinase: Therapeutic Intervention in Cytokine-Mediated Diseases”, Current Medicinal Chemistry, vol. 6, No. 9, pp. 807-823 (1999).
Widder, K.J. et al., eds., Section III: “Prodrugs”, Methods in Enzymology, vol. 112, Academic Press, Inc., publ., pp. 309-396 (1985).
Das Jagabandhu
Hynes John
Leftheris Katerina
Lin Shuqun
Wrobleski Stephen T.
Balasubram Venkataraman
Bristol--Myers Squibb Company
Duncan Laurelee A.
Miano Rosemary M.
O'Brien Maureen P.
LandOfFree
Phenyl-aniline substituted bicyclic compounds useful as... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Phenyl-aniline substituted bicyclic compounds useful as..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Phenyl-aniline substituted bicyclic compounds useful as... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3941807